Clinical Trial Update: A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial entry updates on a Phase 1/2 study of 177Lu-NYM032 Injection for metastatic castration-resistant prostate cancer, noting the trial is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 177Lu-NYM032 Injection (Lutetium-177-NYM032)

Snippet

Sponsor: Norroy Bioscience Co., LTD | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING